Daliresp (roflumilast)

P3, N=3973, Terminated, Chiesi Farmaceutici S.p.A. | Active, not recruiting --> Terminated; Strategic decision by Sponsor; not due to safety reasons

P2, N=120, Not yet recruiting, Ganzhou Hemay Pharmaceutical Co., Ltd

P2, N=45, Active, not recruiting, Children's Hospital Medical Center, Cincinnati | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Mar 2026 | Trial primary completion date: Jun 2025 --> Oct 2025

Roflumilast may offer superior glycemic and oxidative stress control benefits, though neuropathy symptoms control was comparable to ALA. (NCT05369793).

P3, N=3973, Active, not recruiting, Chiesi Farmaceutici S.p.A. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Dec 2025 | Trial primary completion date: Apr 2027 --> Dec 2025

P4, N=1032, Active, not recruiting, Johns Hopkins University | Recruiting --> Active, not recruiting

P4, N=50, Completed, Cairo University

The selective PDE4 inhibitor roflumilast demonstrated potential as a therapeutic agent when combined with specific breast cancer treatments, offering a novel approach in breast cancer therapy.

P1/2, N=0, Withdrawn, Sadat City University | N=80 --> 0 | Recruiting --> Withdrawn

One of these 24 drugs is olanzapine, added to AVRO. Given the short median survival of GB as of mid-2025, the clinician and researcher community will benefit from wider awareness of the anti-GB effects of these four nononcology drugs.

P1, N=20, Active, not recruiting, University of Calgary | Recruiting --> Active, not recruiting

This study highlights the potential use of roflumilast as a chemopreventive agent for patients with chronic obstructive pulmonary disease who are at risk of lung cancer and underscores its relevance for future clinical application and research on phosphodiesterase-4 inhibitors.